GANX
NASDAQGain Therapeutics Inc.
Price$1.25-0.05 (-3.85%)
01:30 PM07:45 PM
News · 26 weeks31+200%
2026-04-192026-10-11
Mix1190d
- Other5(45%)
- SEC Filings4(36%)
- Earnings1(9%)
- Leadership1(9%)
Latest news
25 items- PRSibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicLidia Pieri to serve as Chief Operating Officer and Elena Ardini promoted to Chief Scientific Officer Cyclin D1-targeting folding-interfering degrader advances as Sibylla’s lead program Milan, Italy, October 13, 2026 – Sibylla Biotech today announced key executive appointments, including Usman Azam, MD, as Chief Executive Officer and Gianluca Fuggetta, MSc, MBA, as Chief Financial Officer. Both bring significant international corporate expertise, with Dr. Azam contributing more than 25 years of global biopharmaceutical executive, scientific and clinical development leadership. Co-founder and previous CEO Lidia Pieri, PhD, MBA, will remain with the company in the role of Chief Operating Offi
- PRGain Therapeutics to Attend the 2026 Maxim Growth SummitBETHESDA, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small-molecule therapies, today announced it will participate in the upcoming 2026 Maxim Growth Summit, taking place from October 12th to 14th at The Hard Rock Hotel New York, in New York City. Gain Therapeutics will be meeting with institutional investors in one-on-one meeting sessions and engaging with senior Maxim research analysts throughout the event. If you are interested in meeting with Gain management, please contact your Maxim sales representative to sch
- PRGain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationMDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026 Participants with both high and low baseline levels of GluSph experienced stabilization of MDS-UPDRS motor scores by 12 months Results support disease-modifying potential of rexaceract along with a favorable tolerability profile; no significant safety signals observed in the Phase 1b BETHESDA, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery an
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement DisordersBETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson’s Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea. Details of the poster and presentation are as follows: Poster Title: Long-Term Open-Label Data on the GCase Modulator GT-02287 (Rexaceract) in People with Parkinson’s Disease E-Poster Number: 753 Presentation Date: October 7, 2026 Presentation Time: 12:00-12:10pm KST Locati
- SECGain Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities ConferenceBETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain" or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunities Conference, held September 29th at the Metropolitan Club in New York, NY. Presentation Information Presentation Title: Frontiers in Neuroscience Date: Tuesday, September 29, 2026 Time: 11:00 a.m. ET Registered attendees can request one-on-one meetings with Gain management vi
- PRGain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment ConferenceBETHESDA, Md., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain" or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16 in New York City, NY. On-demand Company Presentation Date and Time: Friday, September 11, 2026; replay available beginning 7:00 a.m. ET Access a replay here or visit the "Investors & Media/News & Events" section of the Company’s website at https://gaintherapeutics
- SECSEC Form 10-Q filed by Gain Therapeutics Inc.10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate UpdateBETHESDA, Md., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update. "The second quarter marked an important period of execution for Gain, highlighted by FDA authorization of our IND for rexaceract, which positions us to advance into Phase 2 clinical development," said Gene Mack, President and CEO of Gain Therapeutics. "The encouraging biomarker and clinical data generated to date continue to support the
- INSIDERSEC Form 4 filed by Director Goldstein Dov A Md4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Nicaise Claude4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Islam Khalid4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Melincoff Gwen A4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Riley Jeffrey Scott4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- INSIDERSEC Form 4 filed by Director Hasler Hans Peter4 - Gain Therapeutics, Inc. (0001819411) (Issuer)
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateBETHESDA, Md., July 16, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack: To our valued Shareholders, As we progress through 2026 and look ahead to delivering continued significant progress, I want to thank you for your steadfast support of Gain Therapeutics. The year has been one of meaningful scientific progress as we achieved critical inflection points related to the clinical development of rexaceract, forme
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s DiseaseIND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA’s decision follows positive Phase 1 results for GT-02287 in both healthy volunteers and people with Parkinson’s disease demonstrating both biomarker and clinical evidence of activity with favorable safety and tolerability GT-02287 is the first allosteric modulator developed from Gain’s Magellan™ AI drug discovery platform to receive IND clearance BETHESDA, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of a
- SECGain Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitBETHESDA, Md., June 10, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, being held in a hybrid format from June 15-16, 2026. Fireside Chat Details Date and Time: Monday, June 15, 2026; replay beginning 7:00 a.m. EDT Access a replay of the fireside chat here or visit the "Investors & Media/News & Events" section of the Compa
- SECGain Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Gain Therapeutics, Inc. (0001819411) (Filer)
- PRGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026MDS-UPDRS scores remained stable and durable across overall study population after 150 days of treatment with GT-02287 Differential response between participants with low and high baseline GluSph continues, with a difference of 4.8 points in the sum of MDS-UPDRS Part II and Part III scores between the two groups at Day 150 Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait BETHESDA, Md., May 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next ge
GANX FAQ
7 questionsWhat does Gain Therapeutics Inc. do?
Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases...Where does GANX stock trade?
Gain Therapeutics Inc. (GANX) is listed on NASDAQ.What sector and industry is GANX in?
Gain Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Gain Therapeutics Inc. go public?
Gain Therapeutics Inc. (GANX) completed its IPO in 2021.What are analysts saying about GANX?
Gain Therapeutics Inc. has had 4 recent analyst actions on file. The most recent action was from Scotiabank: Sector Outperform with a $1200.00 price target on 2025-03-07. Recent price targets range from $700.00 to $2100.00.What companies are similar to GANX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GANX side-by-side with any of them on Quantisnow.How can I track GANX on Quantisnow?
Quantisnow aggregates Gain Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GANX to receive live email and push alerts on every new disclosure.